Amgen's stock took a significant hit following disappointing news from a competitor's clinical trial.
Amgen Inc. (NASDAQ:AMGN) saw its stock price drop by 1.34% yesterday, closing at CA$377.35. This decline was largely due to negative developments in a competitor's drug trial, raising concerns about Amgen's own pipeline.
Investor takeaway: Investors should stay cautious, as recent setbacks for competing therapies may affect Amgen's future prospects, especially in the cardiovascular space.
Advertisement
Amgen's market cap now stands at CA$204 billion.
This market cap reflects a significant valuation drop as investors reassess the company's growth trajectory in light of recent setbacks.
Bull case
Amgen's diverse portfolio, which includes successful products like Repatha, offers some protection against risks linked to its Lp(a) lowering therapies.
Bear case
The failure of Novartis' pelacarsen trial has raised doubts about the effectiveness of Amgen's olpasiran, potentially threatening its market position and leading to further stock declines.
Impact of Novartis' Trial Failure
Advertisement
Amgen's decline was mainly triggered by Novartis' announcement that its pelacarsen drug failed to meet its primary endpoint in a critical cardiovascular outcomes trial. This news alarmed investors, as Amgen's olpasiran operates on a similar mechanism. The market reacted quickly, causing a significant drop in Amgen's stock price as investors reevaluated the viability of its Lp(a) lowering therapies.
Market Reactions and Analyst Downgrades
Following the news, several analysts downgraded Amgen's stock, reflecting concerns over its future growth prospects. BMO Capital Markets lowered its rating to Market Perform, citing increased risks associated with Amgen's pipeline. This downgrade, along with the broader market's reaction to pressures in the healthcare sector, contributed to the stock's downward trend.
Looking Ahead: Investor Sentiment
As Amgen faces these challenges, investor sentiment remains cautious. While the company's strong existing product portfolio may offer some stability, uncertainty surrounding its Lp(a) therapies could lead to more volatility. Investors are advised to keep an eye on upcoming trial results and market developments that could impact Amgen's performance in the near future.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
